B Cell Lymphoma
Conference Coverage
Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies
Conference Coverage
ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma
Conference Coverage
Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL
Conference Coverage
Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL
Conference Coverage
ZUMA-5: Axi-cel yields high response rate in indolent NHL
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...
Conference Coverage
COVID-19–related outcomes poor for patients with hematologic disease in ASH registry
From the Journals
Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia
The presence of “many or very many nevi [moles]” was particularly associated with the risk of CLL.
Conference Coverage
CAR T for all R/R DLBCL patients: The jury is still out
From the Journals
Older age, r/r disease in lymphoma patients tied to increased COVID-19 death rate
Clinical Insights
Efforts to close the ‘AYA gap’ in lymphoma
Feature
Seven things to know about new lymphoma drug tafasitamab